Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | PAM | P19021 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14166378 | 1.00 | DGKA (0.67) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL16615968 | 0.97 | DGKA (0.62) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL19378376 | 0.93 | MAPT (0.58) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL8211006 | 0.92 | DGKA (0.57) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL326500 | 0.92 | DGKA (0.57) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL16062674 | 0.91 | DGKA (0.57) | DGKAMAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL1276448 | 0.89 | NAAA (0.57) | MAPTNAAALMNA | |
| SCHEMBL505594 | 0.89 | NAAA (0.57) | MAPTNAAALMNA | |
| SCHEMBL4735966 | 0.89 | NAAA (0.57) | MAPTNAAALMNA | |
| SCHEMBL9271282 | 0.89 | NAAA (0.57) | MAPTNAAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | claimed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | claimed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | claimed |
| EP-2484347-A1 | Transdermal delivery systems comprising bupivacaine | Durect Corporation (US) | 2012-08-08 | — | — | EP | claimed |
| EP-2117521-B1 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORP (US) | 2012-06-27 | — | — | EP | claimed |
| US-20090060986-A1 | Transdermal delivery systems | DURECT CORPORATION | 2009-03-05 | — | — | US | claimed |
| US-20180110739-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170007549-A1 | Transdermal Delivery Systems | DURECT CORPORATION | 2017-01-12 | — | — | US | disclosed |
| US-8956644-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130317456-A1 | Transdermal Delivery Systems | DURECT CORPORATION (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130273139-A1 | TRANSDERMAL DELIVERY SYSTEMS | DURECT CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8337883-B2 | Transdermal delivery systems | DURECT CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2484347-A1 | Transdermal delivery systems comprising bupivacaine | Durect Corporation (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2117521-B1 | TRANSDERMAL DELIVERY SYSTEMS COMPRISING BUPIVACAINE | DURECT CORP (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20090060986-A1 | Transdermal delivery systems | DURECT CORPORATION | 2009-03-05 | — | — | US | disclosed |